138 results
S-3ASR
AUTL
Autolus Therapeutics plc
28 Mar 24
Automatic shelf registration
4:10pm
in the form of ADSs.
TAXATION
The following summary contains a description of material U.K. and U.S. federal income tax consequences … of the acquisition, ownership and disposition of our ADSs. This summary should not be considered a comprehensive description of all the tax considerations that may
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
................................................................................ 59 16.6 After-Tax Basis .............................................................................................................. 59 17 … ). 1.198 “Sales Tax” means any sales, goods, services, value-added, turnover, consumption, use or similar tax and any tax charged on the import
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
by governments;
differing reimbursement regimes and price controls in certain non-U.S. markets;
negative consequences from changes in tax laws;
compliance … with tax, employment, immigration and labor laws for employees living or traveling abroad, including, for example, the variable tax treatment
10-K
2023 FY
EX-97.1
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
without regard to tax or social security withholdings and other deductions). For any compensation plans or programs that take into account Incentive … with the Listing Standards; or (iii) recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan
8-K
AUTL
Autolus Therapeutics plc
21 Mar 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:21pm
(the “Company”) benefits from the U.K. research and development tax credit regime under the scheme for small or medium-sized enterprises (“SMEs”). Under … and development expenditure tax credit (“RDEC”) to the extent that its research projects are grant funded. The Company has historically accounted
8-K/A
EX-99.1
ivea26
15 Mar 24
Results of Operations and Financial Condition
4:21pm
8-K
EX-99.2
mfgnu
14 Mar 24
Results of Operations and Financial Condition
12:32pm
8-K
EX-99.1
0za0qwzqgu3 ju
14 Mar 24
Results of Operations and Financial Condition
12:32pm
424B5
uz4skfel8pq 8sa
9 Feb 24
Prospectus supplement for primary offering
5:15pm
8-K
EX-1.1
4vhogph
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
EX-10.1
se3n2
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
S-3ASR
zfqa6tjbba
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
EX-4.7
pkqx675xcbr
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
EX-4.9
lfr n863bahqgv
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
EX-4.10
0y3iqpnns rfwr
7 Feb 24
Automatic shelf registration
10:00pm
10-Q
EX-10.1
ob0bai4lk7c8s5e6
9 Nov 23
Quarterly report
4:18pm
10-Q
wixih23fofa onje1jx
9 Nov 23
Quarterly report
4:18pm
6-K
EX-99.3
u98a30sr
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.2
t55ehnsvx8c
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm
6-K
EX-99.1
2sndmeenu4m2u
2 Nov 23
Index to Condensed Consolidated Financial Statements
4:26pm